argenx NV ADR (ARGX)vsCellectis SA (CLLS)
ARGX
argenx NV ADR
$897.85
+0.68%
HEALTHCARE · Cap: $54.94B
CLLS
Cellectis SA
$1.17
-7.14%
HEALTHCARE · Cap: $93.23M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 9169% more annual revenue ($5.92B vs $63.82M). ARGX leads profitability with a 31.7% profit margin vs -102.3%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
CLLS
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+67.5%
Fair Value
$2566.94
Current Price
$897.85
$1669.09 discount
Margin of Safety
+87.3%
Fair Value
$28.65
Current Price
$1.17
$27.48 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 36.3%
Revenue surging 52.1% year-over-year
Earnings expanding 50.6% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 166.9x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -112.3% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 31.7% and operating margin at 36.3%. Revenue growth of 52.1% demonstrates continued momentum.
Bull Case : CLLS
The strongest argument for CLLS centers on Price/Book.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : CLLS
The primary concerns for CLLS are EPS Growth, Market Cap, Piotroski F-Score. Debt-to-equity of 2.06 is elevated, increasing financial risk.
Key Dynamics to Monitor
ARGX profiles as a growth stock while CLLS is a turnaround play — different risk/reward profiles.
CLLS carries more volatility with a beta of 2.91 — expect wider price swings.
ARGX is growing revenue faster at 52.1% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (73/100 vs 21/100), backed by strong 31.7% margins and 52.1% revenue growth. CLLS offers better value entry with a 87.3% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Cellectis SA
HEALTHCARE · BIOTECHNOLOGY · USA
Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors to attack and eradicate cancer cells. The company is headquartered in Paris, France.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?